Welcome to our dedicated page for Meiragtx Holdings Plc news (Ticker: MGTX), a resource for investors and traders seeking the latest updates and insights on Meiragtx Holdings Plc stock.
MeiraGTx Holdings Plc (NASDAQ: MGTX) is a clinical-stage leader in gene therapy innovation, developing transformative treatments for ocular, neurological, and salivary gland disorders. This dedicated news hub provides investors and industry professionals with timely updates on the company’s progress, regulatory milestones, and strategic initiatives.
Access authoritative information directly from corporate announcements and verified sources. Track developments across MeiraGTx’s pipeline including clinical trial results for inherited retinal diseases, Parkinson’s disease research updates, and advancements in radiation-induced xerostomia therapies. The repository also features financial disclosures, manufacturing expansions, and partnership announcements.
Key updates include progress on the company’s proprietary riboswitch platform, AAV vector manufacturing innovations, and regulatory interactions. All content is curated to support informed analysis of MeiraGTx’s position in the gene therapy landscape while maintaining strict compliance with financial reporting standards.
Bookmark this page for streamlined access to essential MGTX updates. Combine our news tracking with Stock Titan’s analysis tools to monitor the company’s progress in advancing genetic medicines from clinical development to potential commercialization.
MeiraGTx Holdings (NASDAQ:MGTX) has appointed Dr. Debra Yu to its Board of Directors. Dr. Yu brings over 30 years of healthcare experience, previously serving as President and Chief Strategy Officer of LianBio. Her background includes senior positions in business development at Pfizer and venture capital firms. CEO Alexandria Forbes highlighted that Dr. Yu's expertise will provide valuable insights as MeiraGTx, a gene therapy company, continues to expand its operations and product pipeline focusing on ocular, neurodegenerative diseases, and xerostomia.
MeiraGTx Holdings plc (NASDAQ:MGTX) announced participation in several key conferences. Alexandria Forbes, Ph.D. will present at:
- Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2022
- Mass General Brigham World Medical Innovation Forum on May 4, 2022
- BofA Securities 2022 Healthcare Conference on May 10, 2022
- 2022 RBC Capital Markets Global Healthcare Conference on May 18, 2022
Webcasts will be available on the company's Investor page.
MeiraGTx Holdings plc (MGTX) reported key advancements in its clinical pipeline, including the initiation of Phase 3 trials for botaretigene sparoparvovec in collaboration with Janssen Pharmaceuticals, resulting in a $30 million milestone payment. The company also shared positive preliminary results from the Phase 1 AQUAx trial for AAV-hAQP1, aimed at treating radiation-induced xerostomia, where 6 of 7 patients showed symptom improvement. As of December 31, 2021, MeiraGTx had cash reserves of $137.7 million, ensuring operational funding through mid-2023. However, net losses increased to $79.6 million.
MeiraGTx has announced the receipt of a $30 million milestone payment from Janssen Pharmaceuticals for achieving a clinical milestone in the Phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy targeting X-linked retinitis pigmentosa (XLRP). The trial is now actively dosing patients, and the company is also eligible for additional milestone payments related to other gene therapy programs in collaboration with Janssen. XLRP is a severe retinal disease, and this therapy aims to improve vision outcomes for patients.
On December 15, 2021, MeiraGTx Holdings plc (NASDAQ: MGTX) will conduct a virtual R&D Day showcasing its innovative gene regulation platforms. The event, led by CEO Alexandria Forbes, will cover topics such as promoter engineering and synthetic riboswitch technology. Participants can register for the event online and access a live webcast, with a replay available on the company's investor page. MeiraGTx aims to transform gene therapy with its proprietary platforms that promise precise gene expression control, targeting ocular, neurodegenerative diseases, and xerostomia.
MeiraGTx Holdings (MGTX) reported promising preliminary data from its Phase 1 AQUAx trial of AAV-hAQP1, aimed at treating grade 2/3 radiation-induced xerostomia (RIX). The results indicate that 6 out of 7 participants showed clinically meaningful improvement in xerostomia symptoms at 90 days. One participant maintained improvement at 24 months. AAV-hAQP1 demonstrated good safety and tolerability. The company plans to initiate a Phase 2 study in late 2022. RIX affects about 170,000 patients in the U.S., revealing a significant unmet medical need.
MeiraGTx Holdings plc (NASDAQ: MGTX) announced a conference call on December 7, 2021, to discuss updates on its Phase 1 AQUAx clinical trial targeting radiation-induced xerostomia. Additionally, a virtual R&D Day will occur on December 15, 2021, focusing on their gene regulation platforms. The AQUAx trial evaluates AAV-hAQP1's safety and its efficacy in improving salivary output in patients post-radiation therapy. The company is pioneering riboswitch gene regulation technology, aiming to address unmet medical needs across multiple areas, including ocular and neurodegenerative diseases.
MeiraGTx Holdings plc (Nasdaq: MGTX) reported its Q3 2021 financial results, revealing a license revenue of $6.9 million, up from $5.1 million in Q3 2020. The net loss for the quarter was $25.9 million, or $0.59 per share, compared to a loss of $6.4 million last year. The company is progressing its Phase 3 Lumeos Trial and the AQUAx Phase 1 study, while also presenting advancements in its riboswitch gene regulation platform. Despite increased R&D expenses of $21.6 million, MeiraGTx has $143.6 million in cash, sufficient for operations into Q2 2023.
MeiraGTx Holdings (NASDAQ: MGTX), a clinical stage gene therapy company, announced participation in upcoming virtual investor conferences. Key presentations include:
- Barclays Gene Editing & Gene Therapy Summit on November 15, 2021, at 2:00 p.m. ET.
- 33rd Annual Piper Sandler Healthcare Conference available from November 22 to December 2, 2021.
- Evercore ISI 4th Annual HealthCONx on November 30, 2021, at 10:05 a.m. ET.
Webcasts of these events will be accessible on their Investors page for 30 days post-presentation.
FAQ
What is the current stock price of Meiragtx Holdings Plc (MGTX)?
What is the market cap of Meiragtx Holdings Plc (MGTX)?
